SEC Filings
Rapport Closes $410.7 Million Raise After Bipolar Trial Clears Significance At p=0.045
The biotech sold stock, notes and private shares on October 30, and now says its cash lasts through the end of 2029.
Rapport Therapeutics (RAPP) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The biotech sold stock, notes and private shares on October 30, and now says its cash lasts through the end of 2029.
Earnings
The drug developer's third-quarter net loss grew to $40.2 million as spending on RAP-219 rose, but October financing lifted its cash position.
SEC Filings
The biotech also placed shares privately and estimated $395.0 million in cash at September 30, saying funds should last through 2029.
SEC Filings
The biotech also priced $150 million of 2.25% convertible notes and a private placement, and says the money funds operations through the end of 2029.
SEC Filings
An 8-K shows RAP-219 met its main goal in a 253-adult mid-stage trial, with 24.6% stopping treatment versus 11.8% on placebo.